www.expressindia.com - Weather | Horoscope | Stocks | RSS
expressindia web city
HomeBlogsCricketAstrologyShopping TendersClassifieds Opinions Hotels
Sign In / Register | Archive
Expressindia » Story

Cipla unveils drug to combat H1N1 virus

Font Size

fe Bureau

Posted: Nov 12, 2009 at 0417 hrs IST

Mumbai Mumbai-based Cipla has launched Oseltamivir, a generic version of Roche’s Tamiflu, used in the treatment of the H1N1 virus, under the brand name, Antiflu, in India. Cipla’s Oseltamivir brand will cost Rs 475 for 10 capsules, and its 75 ml syrup will be similarly priced. Cipla’s drug is also pre-qualified by the World Health Organisation (WHO). The H1N1 virus outbreak from the early part of the year was declared a pandemic in June and continues to spread globally.

On Monday, the health ministry said more than 500 people have died from the flu in India since the first fatality was reported in August, with Maharashtra seeing the largest toll of 207 deaths. More than 14,000 people have tested positive for the flu across India during the period. More than 5,700 people have died worldwide since the virus was first discovered in April.

“Influenza, a perceivably benign condition, kills about 2.5 to 5 lakh people every year worldwide, according to the WHO. These are generally the elderly or those with chronic conditions of the lung, heart or kidney. The fatality pattern this year with the 2009 H1N1 virus has been unusual, with the virus attacking healthy adults and children and pregnant women,” said JA Gogtay, medical director, Cipla. The company's shares closed at Rs 304.75 on the BSE on Wednesday, up 1.43%.

According to YK Hamied, chairman, Cipla, the company has offered to supply Antiflu to the United States. “There is a shortage in the US. We have made an offer. It’s up to them,” he said. Cipla can produce two million doses of Oseltamivir a month if needed, he added.

Discuss this story on expressindia forums
Post Comments
Name* Email ID*
Subject* Country*
Message*
Characters remaining
 
TERMS OF USE: The views, opinions and comments posted are your, and are not endorsed by this website. You shall be solely responsible for the comment posted here. The website reserves the right to delete, reject, or otherwise remove any views, opinions and comments posted or part thereof. You shall ensure that the comment is not inflammatory, abusive, derogatory, defamatory &/or obscene, or contain pornographic matter and/or does not constitute hate mail, or violate privacy of any person (s) or breach confidentiality or otherwise is illegal, immoral or contrary to public policy. Nor should it contain anything infringing copyright &/or intellectual property rights of any person(s).
I agree to the terms of use.

Latest News

Business

Showbiz

Sports

India can't quiz Headley, Rana in US: NSA Jones

Moily announces a new bill to check judicial corruption

Sonia nominates Rosaiah as Andhra CLP leader

Maoists call 48-hour bandh in Jharkhand from tonight

Telangana tense as TRS chief to go on fast for statehood

Everybody free to take own decision: Uddhav on Smita

Cornered Zardari hands over Nuke control to Pak PM Gilani

More
Featured Services
© 2009 The Indian Express Limited. All rights reserved
The Indian Express Group | Advertise With Us | Privacy Policy | Feedback | Work With Us | Site Map